FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2046101516> ?p ?o ?g. }

• W2046101516 endingPage "138" @default.
• W2046101516 startingPage "138" @default.
• W2046101516 abstract "To review the efficacy of phosphodiesterase type 5 inhibitors (PDE5-Is) in lower urinary tract symptoms (LUTS) suggestive of benign prostate hyperplasia (LUTS/BPH).A comprehensive research was conducted to identify all publications relating to benign prostate hyperplasia and treatment with sildenafil, vardenafil and tadalafil. To assess the efficacy, the changes in total international prostate symptom score (IPSS), IPSS subscore including voiding, storage and quality of life (QoL), Benign prostatic hyperplasia Impact Index (BII), maximum urinary flow rate (Qmax) and the International Index of Erectile Function (IIEF) were extracted. A meta-analytical technique was used for the analysis of integrated data from the included studies to evaluate the mean difference in the results.Total IPSS score, IIEF and BII showed a significant improvement in trials in which LUTS/BPH with or without erectile dysfunction (ED) were compared with the placebo. For LUTS/BPH, the mean differences of total IPSS score, IIEF and BII are -2.17, 4.88 and -0.43, P < 0.00001, respectively. For LUTS/BPH with comorbid ED, the mean difference are -1.97, 4.54 and -0.52, P < 0.00001, respectively. PDE5-Is appear to improve IPSS storage, voiding and QoL subscore (mean difference = -0.71, -1.23 and -0.33, P < 0.00001, respectively). Although four doses of tadalafil (2.5, 5, 10 and 20 mg) failed to reach significance in Qmax (mean difference = 0.22, P = 0.10), the 5 mg dose of tadalafil significantly improved the Qmax (mean difference = 0.33, P = 0.03).PED5-Is demonstrated efficacy for improving LUTS in BPH patients with or without ED and could be considered to be the first line treatment for LUTS/BPH." @default.
• W2046101516 created "2016-06-24" @default.
• W2046101516 creator A5064207657 @default.
• W2046101516 creator A5089216154 @default.
• W2046101516 date "2015-01-01" @default.
• W2046101516 modified "2023-09-27" @default.
• W2046101516 title "Are phosphodiesterase type 5 inhibitors effective for the management of lower urinary symptoms suggestive of benign prostatic hyperplasia?" @default.
• W2046101516 cites W1518162929 @default.
• W2046101516 cites W1538235949 @default.
• W2046101516 cites W1554249994 @default.
• W2046101516 cites W1556379330 @default.
• W2046101516 cites W1559582992 @default.
• W2046101516 cites W1590209850 @default.
• W2046101516 cites W1986031402 @default.
• W2046101516 cites W1996950143 @default.
• W2046101516 cites W1997605348 @default.
• W2046101516 cites W2000876723 @default.
• W2046101516 cites W2001938272 @default.
• W2046101516 cites W2006615433 @default.
• W2046101516 cites W2015122735 @default.
• W2046101516 cites W2018377518 @default.
• W2046101516 cites W2024127506 @default.
• W2046101516 cites W2024625397 @default.
• W2046101516 cites W2025969930 @default.
• W2046101516 cites W2038482813 @default.
• W2046101516 cites W2038693293 @default.
• W2046101516 cites W2049932762 @default.
• W2046101516 cites W2050093658 @default.
• W2046101516 cites W2051497077 @default.
• W2046101516 cites W2051838969 @default.
• W2046101516 cites W2056030667 @default.
• W2046101516 cites W2069963496 @default.
• W2046101516 cites W2073978463 @default.
• W2046101516 cites W2074093603 @default.
• W2046101516 cites W2074917601 @default.
• W2046101516 cites W2077404900 @default.
• W2046101516 cites W2078469638 @default.
• W2046101516 cites W2086685901 @default.
• W2046101516 cites W2097777344 @default.
• W2046101516 cites W2106930684 @default.
• W2046101516 cites W2110308314 @default.
• W2046101516 cites W2115613725 @default.
• W2046101516 cites W2123001825 @default.
• W2046101516 cites W2138819549 @default.
• W2046101516 cites W2157648069 @default.
• W2046101516 cites W2167891855 @default.
• W2046101516 doi "https://doi.org/10.5527/wjn.v4.i1.138" @default.
• W2046101516 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4317624" @default.
• W2046101516 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25664256" @default.
• W2046101516 hasPublicationYear "2015" @default.
• W2046101516 type Work @default.
• W2046101516 sameAs 2046101516 @default.
• W2046101516 citedByCount "9" @default.
• W2046101516 countsByYear W20461015162015 @default.
• W2046101516 countsByYear W20461015162016 @default.
• W2046101516 countsByYear W20461015162017 @default.
• W2046101516 countsByYear W20461015162018 @default.
• W2046101516 countsByYear W20461015162020 @default.
• W2046101516 crossrefType "journal-article" @default.
• W2046101516 hasAuthorship W2046101516A5064207657 @default.
• W2046101516 hasAuthorship W2046101516A5089216154 @default.
• W2046101516 hasBestOaLocation W20461015161 @default.
• W2046101516 hasConcept C121608353 @default.
• W2046101516 hasConcept C126322002 @default.
• W2046101516 hasConcept C126894567 @default.
• W2046101516 hasConcept C142724271 @default.
• W2046101516 hasConcept C159110408 @default.
• W2046101516 hasConcept C204787440 @default.
• W2046101516 hasConcept C27081682 @default.
• W2046101516 hasConcept C2776235491 @default.
• W2046101516 hasConcept C2776547966 @default.
• W2046101516 hasConcept C2777562237 @default.
• W2046101516 hasConcept C2778822586 @default.
• W2046101516 hasConcept C2779478474 @default.
• W2046101516 hasConcept C2779929075 @default.
• W2046101516 hasConcept C2779951463 @default.
• W2046101516 hasConcept C2780435053 @default.
• W2046101516 hasConcept C2780816001 @default.
• W2046101516 hasConcept C71924100 @default.
• W2046101516 hasConcept C74534348 @default.
• W2046101516 hasConceptScore W2046101516C121608353 @default.
• W2046101516 hasConceptScore W2046101516C126322002 @default.
• W2046101516 hasConceptScore W2046101516C126894567 @default.
• W2046101516 hasConceptScore W2046101516C142724271 @default.
• W2046101516 hasConceptScore W2046101516C159110408 @default.
• W2046101516 hasConceptScore W2046101516C204787440 @default.
• W2046101516 hasConceptScore W2046101516C27081682 @default.
• W2046101516 hasConceptScore W2046101516C2776235491 @default.
• W2046101516 hasConceptScore W2046101516C2776547966 @default.
• W2046101516 hasConceptScore W2046101516C2777562237 @default.
• W2046101516 hasConceptScore W2046101516C2778822586 @default.
• W2046101516 hasConceptScore W2046101516C2779478474 @default.
• W2046101516 hasConceptScore W2046101516C2779929075 @default.
• W2046101516 hasConceptScore W2046101516C2779951463 @default.
• W2046101516 hasConceptScore W2046101516C2780435053 @default.
• W2046101516 hasConceptScore W2046101516C2780816001 @default.
• W2046101516 hasConceptScore W2046101516C71924100 @default.
• W2046101516 hasConceptScore W2046101516C74534348 @default.

• next